Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.
Posted by rob on July 23, 2006 under Uncategorized | 
Be the First to Comment
A Worldwide Support Network For Chronic Myelogenous Leukemia
Archives
- May 2012
- March 2012
- February 2012
- January 2012
- October 2011
- September 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- April 2007
- March 2007
- February 2007
- January 2007
- December 2006
- November 2006
- October 2006
- September 2006
- August 2006
- July 2006
- June 2006
- May 2006
- April 2006
- March 2006
- February 2006
- January 2006
- December 2005
- November 2005
- October 2005
- September 2005
- August 2005
- July 2005
- June 2005
- May 2005
- April 2005
- March 2005
- February 2005
- January 2005
- December 2004
- November 2004
- October 2004
- September 2004
- August 2004
- July 2004
- June 2004
Recent Posts
- E2F1?dependent pathways are involved in amonafide analogue 7?d?induced DNA damage, G2/M arrest and apoptosis in p53?deficient K562 cells
- Medical conditions and risk of adult myeloid leukemia
- Hematopoietic Interferon Regulatory Factor 8-Deficiency Accelerates Atherosclerosis in Mice.
- BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative disease
- A novel five-way translocation t(7;11;9;22;9)(q22;q13;q34;q11.2;q34) involving Ph chromosome in a patient of chronic myeloid leukemia: a case report
- Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era
- Gastric Antral Vascular Ectasia in a Patient with GIST after Treatment with Imatinib: Case Report and Literature Review
- Spinophilin: a new tumor suppressor at 17q21.
- Metastatic basal cell carcinoma in the era of hedgehog signaling pathway inhibitors
- Genetic testing behavior and reporting patterns in electronic medical records for physicians trained in a primary care specialty or subspecialty.
- Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia
- Long?term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study
- Somatic mutations in the HLA genes of patients with hematological malignancy
- Leukapheresis in management hyperleucocytosis induced complications in two pediatric patients with chronic myelogenous leukemia
- 2??Chloro?4??aminoflavone Derivatives Selectively Targeting Hepatocarcinoma Cells: Convenient Synthetic Process, G2/M Cell Cycle Arrest and Apoptosis Triggers
Add A Comment
You must be logged in to post a comment.